Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.37 |
| ▸ | POLA1 | P09884 | 2/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.34 |
| ▸ | ALB | P02768 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.34 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.34 |
| ▸ | POLG | P54098 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14147838 | 1.00 | PDE3A (0.37) | PDE3APOLA1PDE4DSLC29A1LMNA | |
| SCHEMBL10062708 | 0.93 | POLA1 (0.36) | PDE3APOLA1PDE4DSLC29A1LMNA | |
| SCHEMBL16502047 | 0.93 | POLA1 (0.36) | PDE3APOLA1PDE4DSLC29A1LMNA | |
| SCHEMBL2065433 | 0.93 | POLA1 (0.35) | PDE3APOLA1PDE4DSLC29A1LMNA | |
| SCHEMBL10062712 | 0.92 | FGFR1 (0.39) | PDE3APOLA1PDE4DSLC29A1LMNA | |
| SCHEMBL2064812 | 0.92 | PDE3A (0.36) | PDE3APOLA1PDE4DSLC29A1LMNA | |
| SCHEMBL2065147 | 0.91 | POLA1 (0.34) | PDE3APOLA1PDE4DSLC29A1LMNA | |
| SCHEMBL2065520 | 0.91 | POLA1 (0.37) | PDE3APOLA1PDE4DSLC29A1LMNA | |
| SCHEMBL2065464 | 0.91 | POLA1 (0.35) | PDE3APOLA1PDE4DSLC29A1LMNA | |
| SCHEMBL2065038 | 0.90 | POLA1 (0.36) | PDE3APOLA1PDE4DSLC29A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120565-B1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK SHARP & DOHME (US) | 2012-11-28 | — | — | EP | claimed |
| US-8148349-B2 | Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2012-04-03 | — | — | US | claimed |
| US-20100022468-A1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK SHARP & DOHME LLC | 2010-01-28 | — | — | US | claimed |
| EP-2120565-B1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK SHARP & DOHME (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2120565-B1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK SHARP & DOHME (US) | 2012-11-28 | — | — | EP | disclosed |
| US-8148349-B2 | Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2012-04-03 | — | — | US | disclosed |
| US-20100022468-A1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK SHARP & DOHME LLC | 2010-01-28 | — | — | US | disclosed |
| WO-2008079206-A1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK & CO., INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022468-A1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | RNGTT, NSUN2, RNASE1 | PDE3A 484/4885POLA1 78/4885PDE4D 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.